ALK and non-small cell lung carcinoma: Although drugs targeted to the driver genes can significantly improve patients' prognosis, there is not a definite conclusion about the best treatment for patients with ALK fusion mutations combined with other types of mutations and the impact of concomitant mutations on the survival of NSCLC patients.